EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Cangrelor During Percutaneous Coronary Intervention in Patients With Cardiogenic Shock or Cardiac Arrest

Oskar Love Emilsson, Moman A Mohammad, Per Grimfjärd, Jonas Persson, Irene Santos-Pardo, David Erlinge, Sasha Koul

JACC: Cardiovascular Interventions · 2025-04 · 18 (7) · 853-862

DOI: 10.1016/j.jcin.2025.01.451 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JACC: Cardiovascular Interventions, 2025-04. Verfasst von Oskar Love Emilsson und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Lund University, Lund, Sweden. Electronic address: love.emilsson@med.lu.se. Hauptthemen laut MEDLINE: Adenosine Monophosphate, Heart Arrest, Myocardial Infarction, Percutaneous Coronary Intervention. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Skanes universitetssjukhus Lund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Little is known regarding treatment with cangrelor during percutaneous coronary intervention (PCI) in patients with myocardial infarction complicated by cardiogenic shock or cardiac arrest. OBJECTIVES: The aim of this study was to investigate the effects of such cangrelor treatment during PCI in patients with myocardial infarction complicated by cardiogenic shock or cardiac arrest. METHODS: The study population included patients undergoing PCI (2016-2022) for myocardial infarction with cardiogenic shock or cardiac arrest from SCAAR (Swedish Coronary Angiography and Angioplasty Registry). Propensity score (PS)-matched groups were compared regarding major adverse cardiovascular events (MACE) within 30 days, in-hospital major bleeding, and all-cause mortality within 30 days. RESULTS: A total of 3,014 patients with cardiogenic shock or cardiac arrest were included, 1,011 receiving and 2,003 not receiving cangrelor. In the PS-matched analysis regarding patients with cardiogenic shock (n = 994), the risk ratio (with vs without cangrelor) was 0.82 (95% CI: 0.71-0.94) for MACE, with an absolute risk reduction of 8.9 percentage points (95% CI: 2.7-15 percentage points) (number needed to treat = 12); 1.60 (95% CI: 0.93-2.76) for major bleeding; and 0.81 (95% CI: 0.70-0.94) for mortality, with an absolute risk reduction of 8.9 percentage points (95% CI: 2.7-15 percentage points) (number needed to treat = 12). In the PS-matched analysis regarding patients with cardiac arrest (n = 1,138), the risk ratio was 1.01 (95% CI: 0.87-1.18) for MACE; 2.26 (95% CI: 1.25-4.11) for major bleeding, with an absolute risk increase of 3.5 percentage points (95% CI: 1.0-5.7 percentage points); and 0.97 (95% CI: 0.83-1.13) for all-cause mortality. CONCLUSIONS: For patients with cardiogenic shock, administration of cangrelor during PCI was associated with a lower risk for both MACE and all-cause mortality. For patients with cardiac arrest, no such benefit was observed, and a higher risk for major bleeding was found.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adenosine MonophosphateHeart ArrestMyocardial InfarctionPercutaneous Coronary InterventionPlatelet Aggregation InhibitorsShock, CardiogenicAgedAged, 80 and overFemaleHumansMaleMiddle AgedHemorrhageRegistriesRetrospective StudiesRisk AssessmentRisk FactorsTime FactorsTreatment Outcome

Stichwörter der Autor:innen

cangrelorcardiac arrestcardiogenic shockmyocardial infarctionpercutaneous coronary intervention

Substanzen

Adenosine MonophosphatecangrelorPlatelet Aggregation Inhibitors

Autor:innen und Institutionen

  • Department of Cardiology, Lund University, Lund, Sweden. Electronic address: love.emilsson@med.lu.se.
  • Department of Cardiology, Lund University, Lund, Sweden; Department of Cardiology, Skåne University Hospital, Lund, Sweden.
  • Department of Medicine, Västerås Hospital, Västerås, Sweden; Department of Medical Sciences, Cardiology, Uppsala University, Uppsala, Sweden.
  • Division of Cardiovascular Medicine, Department of Clinical Sciences, Karolinska Institute, Danderyd University Hospital, Stockholm, Sweden.
  • Department of Clinical Science and Education, Karolinska Institute, Unit of Cardiology, Södersjukhuset, Stockholm, Sweden.

Förderung

  • Skanes universitetssjukhus Lund

Zitieren

APA

Emilsson, O. L., Mohammad, M. A., Grimfjärd, P., Persson, J., Santos-Pardo, I., Erlinge, D., & Koul, S. (2025). Cangrelor During Percutaneous Coronary Intervention in Patients With Cardiogenic Shock or Cardiac Arrest. JACC: Cardiovascular Interventions, 18(7), 853-862. https://doi.org/10.1016/j.jcin.2025.01.451

Vancouver

Emilsson OL, Mohammad MA, Grimfjärd P, Persson J, Santos-Pardo I, Erlinge D, et al. Cangrelor During Percutaneous Coronary Intervention in Patients With Cardiogenic Shock or Cardiac Arrest. JACC: Cardiovascular Interventions. 2025;18(7):853-862. doi:10.1016/j.jcin.2025.01.451

BibTeX
@article{Emilsson2025,
  author = {Emilsson, Oskar Love and Mohammad, Moman A and Grimfjärd, Per and Persson, Jonas and Santos-Pardo, Irene and Erlinge, David and Koul, Sasha},
  title = {Cangrelor During Percutaneous Coronary Intervention in Patients With Cardiogenic Shock or Cardiac Arrest},
  journal = {JACC: Cardiovascular Interventions},
  year = {2025},
  volume = {18},
  number = {7},
  pages = {853--862},
  doi = {10.1016/j.jcin.2025.01.451}
}
Kostenlos starten →